Myriad Genetics
MYGN
192 hedge funds and large institutions have $943M invested in Myriad Genetics in 2020 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 62 increasing their positions, 64 reducing their positions, and 29 closing their positions.
55% more call options, than puts
Call options by funds: $2.59M | Put options by funds: $1.67M
14% more capital invested
Capital invested by funds: $828M → $943M (+$115M)
0.36% more ownership
Funds ownership: 97.95% → 98.31% (+0.36%)
3% less repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 64
2% less funds holding
Funds holding: 196 → 192 (-4)
14% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$13.6M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$12.7M |
| 3 |
GCM
Glenview Capital Management
New York
|
+$12M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$8.16M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$5.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$13.2M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$7.71M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$5.75M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$3.91M |
| 5 |
PA
Pinnacle Associates
New York
|
-$3.73M |
MYGN Hedge Fund Activity: Q3 2020 in Review
192 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q3 2020, worth a combined $943M — up 14% from $828M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of MYGN and 25 opened new positions — a net loss of 4 holders — while 64 trimmed existing stakes and 62 added.
The largest buyer was Millennium Management, adding an estimated $13.6M. The largest seller was State Street, cutting an estimated $13.2M.
- 192 institutional investors held Myriad Genetics (MYGN) as of Q3 2020, down from 196 in Q2 2020.
- Funds reported $943M of Myriad Genetics stock for Q3 2020, up 14% quarter-over-quarter.
- 25 funds opened new Myriad Genetics positions in Q3 2020 and 29 closed out, a net change of -4 holders.
- The largest Myriad Genetics buyer in Q3 2020 was Millennium Management, an estimated $13.6M added.
- The largest Myriad Genetics seller in Q3 2020 was State Street, an estimated $13.2M sold.
Based on aggregated 13F filings for Q3 2020.